# CMB International Securities | Equity Research | Company Update



#### 招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Bank

# Xtep (1368 HK)

# Upbeat guidance with multiple growth drivers

We are satisfied by Xtep's accelerated growth in 4Q21, given weak macro and COVID-19 environment. Following its guidance raised, we maintain BUY and revised up SOTP-based TP to HK\$16.43, implying ~30x FY22E P/E (unchanged). We think it is still attractive at 23x FY22E P/E.

- 4Q21 numbers were roughly in-line and Jan-TD in 2022E stay strong. Xtep retail sales grew by 20-25% YoY in 4Q21, and speeded up from midteens in 3Q21, which is impressive given tougher macro and COVID environment. Growth for Xtep adult/ kids/ e-commerce were double-digit/ 40%+/ high double-digit. Inventory to sales ratio was 4 months and retail discounts was 20% to 25% off in 4Q21, both are the same as 3Q21. Noted that the sell-through rate was satisfactory, ~80% for 3Q21 and ~60% for 4Q21, which should be better than the industry. Following a 30%+ retail sales growth in FY21E, momentum stayed strong at 20%+ in Jan-TD 2022E.
- Positive profit alert for FY21E. Xtep also reported a 70%+ NP growth in FY21E, which was a result of: 1) more 9th gen. stores, 2) product and brand upgrades (XDNA, 160X and 260X series), 3) ramp up of Kids and ecommerce and 4) core brand's GP margin expansion.
- Revised up sales growth target to 25%+ (from 20%+) in FY22E. For FY22E, management is now expecting 25%+ sales growth (30%+ in 1H22E) for Xtep core brand, 50%+ for kids, 30%+ for new brands (K-Swiss and Palladium) and 50%+ for JV (Saucony & Merrell). We are confident as well, thanks to: 1) ramp up of 9th gen. stores (large size at 200+ sq m, better locations, higher items per tickets at 3.0+, 10%+ volume growth), 2) higher ASP through brand and product upgrades, 3) 200-300 new stores for Xtep's adult and 200-300/ 100 more shop-in-shops for kids/ XNDA and 4) rapid growth from kids and e-commerce. We also expect both GP and OP margin to gradually trend up in FY22E, with A&P expenses still at 11-13% of sales.
- There is also a management change, but we think it is positive. Xtep hired a new CEO lately for the Xtep brand. He worked in Nike/ Topsports for 20+ years and is likely to help Xtep's channel expansion (e.g. malls). The original CEO will become CEO of the new brands (K-Swiss and Palladium). We believe Xtep is slightly ahead of schedule to achieve RMB 24bn sales target (in its 5-year plan) and all these changes are part of the process.
- Maintain BUY and lift TP to HK\$ 16.43. We revised up FY21E/ 22E/ 23E NP by 0%/ 7%/ 5% to factor in faster sales growth, more stores and greater operating leverage. We lift TP to HK\$ 16.43, based on SOTP valuation (26x FY22E P/E for Xtep, cost for K&P and 2.0x P/S for JV), implying ~30x for group, which is reasonable given 43% NP CAGR in FY20-23E.

#### **Earnings Summary**

J					
(YE 31 Dec)	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	8,183	8,172	10,070	12,558	14,567
YoY growth (%)	28.2	(0.1)	23.2	24.7	16.0
Net income (RMB mn)	728	513	880	1,168	1,509
EPS (RMB)	0.302	0.206	0.346	0.459	0.592
YoY growth (%)	2.3	(31.6)	67.5	32.7	29.2
Consensus EPS (RMB)	n/a	n/a	0.338	0.434	0.541
P/E (x)	38.2	52.6	31.0	23.3	18.1
P/B (x)	4.1	3.8	3.5	3.3	3.0
Yield (%)	1.5	1.1	1.9	2.6	3.3
ROE (%)	10.5	7.0	11.3	14.0	16.7
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIS estimates

# **BUY (Maintain)**

 Target Price
 HK\$16.43

 (Previous TP
 HK\$15.41)

 Up/Downside
 +27.3%

 Current Price
 HK\$12.90

#### **China Sportswear Sector**

## Walter Woo (852) 3761 8776 walterwoo@cmbi.com.hk

# Raphael Tse (852) 3900 0856 raphaeltse@cmbi.com.hk

Stock Data	
Mkt Cap (HK\$ mn)	33,931
Avg 3 mths t/o (HK\$ mn)	166.22
52w High/Low (HK\$)	16.32/3.31
Total Issued Shares (mn)	2,630.3
Source: Bloomberg	

Shareholding Structure	
Mr Ding Shui Po & Family	52.28%
JP Morgan Chase	4.61%
ICBC Credit Suisse AM	3.02%
Employee incentive scheme	4.01%
Free Float	36.08%
Source: HKEx, Bloomberg	

# Share Performance Absolute Relative 1-mth 3.9% 0.7% 3-mth 30.8% 33.9% 6-mth -5.7% 7.5%

243.1%

301.0%

Source: Bloomberg

12-mth

# 12-mth Price Performance (HKS) 17.0 14.0 11.0 8.0 5.0 2.0 1/2021 4/2021 7/2021 10/2021

Source: Bloomberg

# Auditor: Ernst & Young

#### **Related Reports**

- Xtep (1368 HK, BUY) Slight beat in 3Q21 and guidance maintained – 20 Oct 2021
- Xtep (1368 HK, BUY) Stable 2H21E and upbeat long-term guidance – 24 Aug 2021
- Xtep (1368 HK, BUY) Guidance raised after positive profit alert – 15 Jul 2021



# **Focus charts**

Figure 1: Sum of the parts (SOTP) valuation for Xtep Int'l

Sum of the parts valuation	Targeted price per share (HK\$)	Targeted market cap (HK\$ mn)	Targeted market cap (RMB mn)	Target ratio (x)	Valuation method	FY22E sales (RMB mn)	FY22E net profit (RMB mn)	Remarks
Xtep core brand	15.39	39,199	32,535	26.0	FY22E P/E	11,027	1,251	Based on 31% NP FY20-23E CAGR
K-Swiss and Palladium	0.79	2,014	1,672	n/a	M&A costs	1,272	(57)	Implying a 1.5x FY22E P/S
Saucony and Merrell JV	0.25	626	519	2.0	FY22E P/S	260	(26)	Based on 2.0x FY22E P/S
Total (RMB)	16.43	41,839	34,726			12,558	1,168	Implying a 30x FY22E P/E
Number of shares (mn) CNYHKD FX rate	2,547 1.2048							
Current price (HKD)	12.90							
Upside (%)	27.3%							

Source: Bloomberg, CMBIS estimates

Figure 2: Xtep Int'l performance by brand segment

Sales (RMB mn)	FY19	FY20	FY21E	FY22E	FY23E	FY24E	FY25E	FY20-23E CAGR
Xtep core brand	7,707	7,101	8,911	11,027	12,701	14,153	15,606	21.4%
K-swiss and Palladium	466	999	989	1,272	1,432	1,614	1,822	12.7%
Saucony and Merrell JV	10	72	170	260	434	642	862	82.3%
Total	8,183	8,172	10,070	12,558	14,567	16,410	18,291	21.3%
Net profit (RMB mn)	FY19	FY20	FY21E	FY22E	FY23E	FY24E	FY25E	FY20-23E CAGR
Xtep core brand	790	656	1,016	1,251	1,480	1,710	1,964	31.2%
K-swiss and Palladium	(60)	(126)	(93)	(57)	16	67	112	-150.5%
Saucony and Merrell JV	(2)	(17)	(42)	(26)	13	32	60	-191.5%
Total	728	513	880	1,168	1,509	1,809	2,137	43.3%
NP margin	FY19	FY20	FY21E	FY22E	FY23E	FY24E	FY25E	
Xtep core brand	10.2%	9.2%	11.4%	11.3%	11.7%	12.1%	12.6%	
K-swiss and Palladium	-12.9%	-12.6%	-9.4%	-4.5%	1.1%	4.2%	6.2%	
Saucony and Merrell JV	-19.6%	-23.7%	-25.0%	-10.0%	3.0%	5.0%	7.0%	
Total	8.9%	6.3%	8.7%	9.3%	10.4%	11.0%	11.7%	

Source: Company data, CMBIS estimates



# **Operating numbers**

Figure 3: Sportswear brands sales growth trend

Anta brand's retail sales 20%-  Core brand +ve	9.0% 6.0% •25% Mid- eens	25.0% 27.0% +ve Low- teens	20.0%	31.0% 23.0%	24.0% 16.0%	22.0%	27.0%	23.0%	-4.0%	1.0%	8.0%	19.0%	42.0%	9.0%	1.0%	
Anta brand's SSSG  Anta brand's retail sales 20%- Core brand +ve te	<b>25%</b> Mid-	+ve Low-		23.0 /6			11.0%	15.0%	-58.0%	0.0%	-5.0%	7.0%	156.0%	-16.0%	-15.0%	
Core brand +ve	Mid-				10.070	14.0%	11.070	13.0 /6	-30.0 /6	0.076	-3.0 /8	7.070	130.078	-10.0 /6	-13.076	
Core brand te		teens	+ve Mid- teens	+ve Mid-	+ve Low- teens	+ve Mid- teens	+ve Mid- teens	+ve High- teens	-ve 20%- 25%	-ve LSD	+ve LSD	+ve LSD	40%-45%	35%-40%	+ve Low- teens	14.0%
Kids over		+ve HSD	+ve Low- teens	+ve HSD	+ve HSD	+ve Low- teens	+ve Low- teens	+ve HSD	-ve 20%- 25%	-ve LSD	-ve MSD	-ve MSD	35%-40%	35%-40%	+ve HSD	
	40%	over 25%	Over 25%	Over 25%	Over 20%	30%	Over 25%	25%	-ve 20%- 25%	+ve MSD	+ve Low- teens	-ve Low- teens		Over 20%	+ve MSD	
Online over	40%	over 25%	Over 20%	Over 25%	+ve Mid- teens	25%	35%	Over 40%	+ve MSD	Over 40%	Over 50%	Over 25%	Over 60%	Over 45%	20%-25%	
Non-Anta brands (FILA/   80%-	85%	90%-95%	90%-95%	80%-85%	65%-70%	55%-60%										
FILA brand's retail sales							50%-55%	50%-55%	-ve MSD	+ve Low- teens	20%-25%	25%-30%	75%-80%	30%-35%	+ve MSD	12.0%
Classic/ Core brand								Over 40%	-ve 20%- 25%	+ve MSD	+ve MSD	+ve MSD	80%	Over 20%	Flat	
Kids								Over 70%	-ve LSD	Over 30%	Over 30%	Over 20%	100%	Over 40%	+ve Mid- teens	
Fusion								Over 100%	+ve MSD	Over 70%	Over 50%	Over 50%	150%	Over 80%	+ve Mid- teens	
Online								Over 70%	160%	Over 80%	Over 90%	70%-80%	Over 40%	Over 40%	20%-25%	
Other brands							30%-35%	25%-30%	-ve HSD	25%-30%	50%-55%	55%-60%	115%- 120%	70%-75%	35%-40%	
Descente				Over 100%	Over 100%	Over 90%	50%	50%	+ve Mid- teens	Over 60%	90%	Over 80%	150%	100%	50%	
Kolon						15%	20%	20%	-ve High- teens	+ve LSD	20%-25%		Over 75%	40%	30%	
	ens	+ve HSD	+ve Low- teens	+ve Mid- teens	+ve Mid- teens	teens	+ve High- teens	+ve Low- twenties	n/a	-ve MSD	+ve LSD	+ve Low- teens	n/a	+ve Low 80%	+ve High 20%	
Direct retail +ve I	Low- eens	+ve HSD	+ve HSD	+ve MSD	+ve HSD	+ve Low- teens	+ve Low- teens	+ve High- teens	n/a	-ve High- teens	-ve MSD	+ve HSD	n/a	+ve Low 90%	+ve Low 30%	
Wholesales +ve N	-	+ve LSD	+ve HSD	+ve MSD	+ve Low- teens	+ve Low- teens	+ve Low- teens	+ve Mid- teens	n/a	-ve Low- teens	-ve MSD	+ve MSD		+ve Low 70%	+ve Mid 20%	
	High 30%	+ve Mid- 30%	+ve High 20%	+ve Mid 50%	+ve High 30%	+ve Mid 30%	+ve Mid 50%	+ve Low 40%	+ve Low- teens	+ve Mid 20%	+ve High 30%	+ve Low 30%		+ve High 80%	+ve Mid 30%	
Li Ning group's retail sa	Mid-´ ens	+ve Low- teens	+ve Mid- teens	+ve High- teens	+ve Low 20%-25%	+ve Low 20%-25%	+ve Low 30%-35%	+ve Mid 30%-40%	-ve High- teens	-ve MSD	+ve MSD	+ve Mid- teens	_	+ve Low 90%	+ve Low 40%	29.0%
Direct retail Low 2	20%- 30%	+ve Mid- teens	+ve Mid- teens	+ve HSD	+ve Low- teens	+ve HSD	+ve Mid- teens	+ve High-	-ve Mid 30%	-ve Low- teens	Flat	+ve MSD	+ve Low 90%	+ve High 80%	+ve Mid 30%	
Wholesales +ve N	MSD	+ve MSD	+ve Low- teens	+ve Low- teens	+ve Low 20%-25%	+ve Mid- 20%	+ve Mid- 30%	+ve Low 40%	-ve High- teens	-ve HSD	-ve LSD	+ve Low- teens		+ve Low 90%	+ve High 30%	
	High 30%	+ve High 30%	+ve Low 30%	+ve Mid 50%	+ve Low 40%	+ve High 20%	+ve Low 50%	+ve Low 40%	+ve Low- teens	+ve High 20%	+ve Low 40%	+ve Mid 30%	100%	+ve High 90%	+ve Mid 50%	
Xtep's SSSG +ve L	Low-	+ve Mid-	+ve Mid-		+ve Low-	+ve Low-	10%	+ve Low-								
Xtep's retail sales	ens	teens	teens	teens	Over 20%	Over 20%		Over 20%	-ve 20%-	-ve LSD	+ve MSD	+ve HSD	Mid 50%-	30%-35%	+ve Mid-	20%-25%
361 Degrees' SSSG +ve I	HSD	+ve HSD	+ve MSD	Flat	+ve LSD	+ve LSD	+ve LSD	+ve LSD	25%				60%		teens	
361 Degree's retail sales									-ve 20%- 25%	-ve Low- teens	-ve HSD	+ve LSD	+ve High- teens	15%-20%	+ve Low- teens	
Pou Sheng's SSSG 10	0.1%	2.2%	8.9%	8.7%	8.4%	4.2%	6.0%	1.9%	-32.5%	-17.8%						
	7.7%	17.7%	24.4%	22.0%	19.9%	18.9%	21.9%	19.1%	-25.1%	0.3%	-0.3%	1.0%	47.8%	-15.0%	-25.1%	-26.7%
	Mid High		+ve MSD	+ve LSD	-ve LSD	+ve MSD	+ve Mid to High	+ve Mid to High	-ve Low to Mid SD	-ve MSD	+ve Low to Mid SD	+ve MSD	+ve HSD	+ve Mid to High	-ve High- teens	
Dong Xiang's retail sales	SD	SD			+ve MSD	+ve MSD	+ve Mid- teens	+ve Low- teens	-ve 25%- 30%	-ve Low-	+ve MSD	+ve Low-		+ve Low to Mid-	ve Mid to High-	
							teens	teens				teens		teens	teens	
Direct retail +ve I	HSD	Flat	+ve Low- teens	+ve HSD	Flat	+ve LSD	+ve HSD	+ve MSD	-ve 30%- 35%	-ve Low- teens	Flat	+ve MSD				
E- Commerce					+ve 35%- 45%	+ve 30%- 35%	+ve 55%- 60%	+ve 40%- 45%	-ve Low- teens	+ve 30%- 35%	+ve 30%- 35%	+ve 20%- 30%				

Source: Company data, CMBIS estimates, \*Nike's year end is in May (e.g. 4Q18 calendar year = 2Q19 fiscal year = Sep-Nov 2018)



# **Earnings revision**

Figure 4: Earnings revision

		New			Old			Diff (%)	
RMB mn	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Revenue	10,070	12,558	14,567	10,070	11,967	13,888	0.0%	4.9%	4.9%
Gross profit	4,176	5,269	6,225	4,176	5,047	5,961	0.0%	4.4%	4.4%
EBIT	1,453	1,855	2,284	1,453	1,738	2,169	0.0%	6.7%	5.3%
Net profit att.	880	1,168	1,509	880	1,089	1,431	0.0%	7.2%	5.5%
Diluted EPS (RMB)	0.346	0.459	0.592	0.346	0.428	0.562	0.0%	7.2%	5.5%
Gross margin	41.5%	42.0%	42.7%	41.5%	42.2%	42.9%	0ppt	-0.2ppt	-0.2ppt
EBIT margin	14.4%	14.8%	15.7%	14.4%	14.5%	15.6%	0ppt	0.2ppt	0.1ppt
Net profit att. margin	8.7%	9.3%	10.4%	8.7%	9.1%	10.3%	0ppt	0.2ppt	0.1ppt

Source: Company data, CMBIS estimates

Figure 5: CMBIS estimates vs consensus

		CMBIS			Consensus		Diff (%)			
RMB mn	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	
Revenue	10,070	12,558	14,567	9,933	12,213	14,801	1.4%	2.8%	-1.6%	
Gross profit	4,176	5,269	6,225	4,135	5,130	6,258	1.0%	2.7%	-0.5%	
EBIT	1,453	1,855	2,284	1,343	1,681	2,076	8.2%	10.4%	10.0%	
Net profit att.	880	1,168	1,509	872	1,117	1,395	1.0%	4.6%	8.2%	
Diluted EPS (RMB)	0.346	0.459	0.592	0.338	0.434	0.541	2.1%	5.7%	9.5%	
Gross margin	41.5%	42.0%	42.7%	41.6%	42.0%	42.3%	-0.2ppt	-0.1ppt	0.5ppt	
EBIT margin	14.4%	14.8%	15.7%	13.5%	13.8%	14.0%	0.9ppt	1ppt	1.7ppt	
Net profit att. margin	8.7%	9.3%	10.4%	8.8%	9.1%	9.4%	0ppt	0.2ppt	0.9ppt	

Source: Company data, CMBIS estimates



# **Assumptions**

Figure 6: Major assumptions

Major assumptions	FY19A	FY20A	FY21E	FY22E	FY23E
Sales by segment (RMB mn)					
Shoes	4,653	5,047	6,344	8,073	9,424
Apparels	3,344	2,964	3,557	4,304	4,949
Accessories	185	161	169	181	194
Total	8,183	8,172	10,070	12,558	14,567
Sales by segment growth (%)					
Shoes	18.6%	8.5%	25.7%	27.3%	16.7%
Apparels	43.7%	-11.4%	20.0%	21.0%	15.0%
Accessories	41.0%	-12.9%	5.0%	7.0%	7.0%
Total	28.2%	-0.1%	23.2%	24.7%	16.0%
Sales by segment (RMB mn)					
Mass market	7,707	7,101	8,911	11,027	12,701
Athleisure	466	999	989	1,272	1,432
Professional sports	10	72	170	260	434
Total	8,183	8,172	10,070	12,558	14,567
Sales by segment growth (YoY)					
Mass market	20.7%	-7.9%	25.5%	23.7%	15.2%
Athleisure	n/a	114.4%	-1.0%	28.6%	12.6%
Professional sports	n/a	609.9%	137.0%	52.8%	67.2%
Total	28.2%	-0.1%	23.2%	24.7%	16.0%
Sales network					
Xtep	5,279	4,971	4,822	5,039	5,240
Xtep kids	850	800	1,000	1,150	1,242
Oversea stores	250	250	250	300	300
Total	6,379	6,021	6,072	6,489	6,782
GP margins	43.4%	39.1%	41.5%	42.0%	42.7%
Opex breakdown					
A&P / sales	14.4%	11.2%	11.1%	11.3%	11.5%
Staff costs/ sales	11.0%	12.1%	11.4%	11.0%	10.6%
R&D / sales	2.4%	2.7%	2.6%	2.4%	2.3%
D&A / sales	1.7%	2.0%	2.5%	2.1%	1.9%
Provisions (write backs) / sales	-0.9%	0.7%	0.0%	0.0%	0.0%
Rental / sales	0.1%	0.1%	1.0%	1.2%	1.3%
Selling & distribution costs / sales	21.0%	18.8%	18.9%	18.7%	18.8%
Admin expenses / sales	11.1%	12.9%	11.3%	11.0%	10.6%
Total	32.1%	31.7%	30.2%	29.7%	29.4%
OP margins	15.1%	11.2%	14.4%	14.8%	15.7%
Effective tax rate	34.8%	33.7%	32.0%	31.0%	30.0%
Net profit att. margins	8.9%	6.3%	8.7%	9.3%	10.4%
Net profit att. growth (%)	10.8%	-29.5%	71.6%	32.7%	29.2%

Source: Company data, CMBIS estimates



# **Valuation**

Figure 7: Peers valuation table

			12m TP	Price	Up/ Down-	Mkt. Cap	Year	P/E	(x)	P/B	(x)	ROE (%)	3yrs PEG (x)	Yield (%)
Company	Ticker	Rating	(LC)	(LC)	side	(HK\$mn)	End	FY1E	FY2E	FY1E	FY2E	FY1E	FY1E	FY1E
H shares Spo	<u>rtswear</u>													
Xtep Intl	1368 HK	BUY	16.43	12.90	27%	33,931	Dec-20	31.0	23.3	3.5	3.2	9.5	0.7	1.9
Anta Sports	2020 HK	BUY	156.06	114.00	37%	308,180	Dec-20	32.7	25.7	8.3	6.8	30.5	0.9	1.1
Li Ning	2331 HK	BUY	102.84	76.85	34%	201,082	Dec-20	43.3	34.5	13.0	10.0	33.2	8.0	0.7
361 Degrees	1361 HK	NR	n/a	3.83	n/a	7,919	Dec-20	11.6	10.3	0.9	0.8	7.7	0.5	1.2
Topsports	6110 HK	NR	n/a	7.67	n/a	47,563	Feb-21	13.5	11.3	3.5	3.0	26.5	0.8	3.9
Pou Sheng	3813 HK	NR	n/a	1.22	n/a	6,498	Dec-20	6.9	4.5	0.6	0.5	11.6	0.1	1.6
China DX	3818 HK	NR	n/a	0.68	n/a	4,004	Mar-21	n/a	5.0	0.3	0.3	(0.5)	0.0	n/a
							Avg.	23.2	16.4	4.3	3.5	16.9	0.6	1.7
							Med.	22.2	11.3	3.5	3.0	11.6	0.7	1.4
International S	<u>portswear</u>													
Nike Inc	NKE US	NR	n/a	148.18	n/a	1,824,012	May-21	40.0	30.8	16.6	15.1	48.3	2.6	8.0
Adidas	ADS GY	NR	n/a	252.35	n/a	430,266	Dec-20	34.3	26.2	6.6	6.0	29.0	0.5	1.3
Puma	PUM GY	NR	n/a	93.16	n/a	124,712	Dec-20	46.6	32.4	7.2	6.3	16.3	0.5	0.6
Under Armour	UAA US	NR	n/a	18.86	n/a	64,262	Dec-20	24.5	24.8	4.4	3.7	25.2	(0.1)	0.0
Lululemon	LULU US	NR	n/a	328.98	n/a	331,110	Jan-21	42.7	35.8	14.4	11.3	36.1	1.3	0.0
Skechers	SKX US	NR	n/a	43.63	n/a	52,929	Dec-20	17.4	14.6	2.2	1.9	15.0	0.2	0.0
Vf Corp	VFC US	NR	n/a	72.25	n/a	220,910	Apr-21	22.7	19.6	7.5	6.9	37.4	0.4	2.7
Columbia	COLM US	NR	n/a	91.27	n/a	46,336	Dec-20	19.2	16.6	3.0	2.7	16.3	0.3	1.2
Wolverine	WWW US	NR	n/a	26.32	n/a	16,876	Jan-21	12.5	10.0	3.3	2.8	(12.9)	(0.1)	1.5
Mizuno Corp	8022 JP	NR	n/a	2182.00	n/a	3,956	Mar-21	16.3	12.2	0.5	0.5	7.7	1.2	2.3
Asics Corp	7936 JP	NR	n/a	2291.00	n/a	29,669	Dec-20	75.5	28.8	3.2	3.0	4.3	(0.4)	1.0
							Avg.	32.0	22.9	6.3	5.5	20.2	0.6	1.0
							Med.	24.5	24.8	4.4	3.7	16.3	0.4	1.0

Source: Bloomberg, CMBIS estimates



# **Financial Summary**

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue	8,183	8,172	10,070	12,558	14,567	EBIT	1,234	918	1,453	1,855	2,284
Footwear	4,653	5,047	6,344	8,073	9,424	D & A	185	318	331	343	349
Apparel	3,344	2,964	3,557	4,304	4,949	Change in working capital	36	(320)	(623)	(797)	(651)
Accessories	185	161	169	181	194	Income tax paid	(334)	(325)	(417)	(532)	(655)
						Others	(343)	(272)	(106)	(114)	(113)
Cost of goods sold	(4,632)	(4,973)	(5,895)	(7,290)	(8,342)	Net cash from operating	778	320	638	756	1,213
Gross profit	3,550	3,198	4,176	5,269	6,225						
Other income	308	307	322	314	335	Capex & investments	(97)	(207)	(151)	(188)	(219)
						Associated companies	(35)	(20)	-	-	-
Operating expenses	(2,625)	(2,588)	(3,045)	(3,728)	(4,276)	Interest received	-	-	-	-	-
S & D costs	(1,718)	(1,537)	(1,903)	(2,345)	(2,737)	Others	(1,913)	800	-	-	-
Admin exp.	(711)	(827)	(880)	(1,082)	(1,204)	Net cash from investing	(2,045)	573	(151)	(188)	(219)
R&D	(195)	(223)	(262)	(301)	(335)						
Other operating expenses	-	-	-	-	-	Equity raised	1,187	31	-	-	-
EBIT	1,234	918	1,453	1,855	2,284	Net change in bank loans	386	(77)	1,003	-	-
						Dividend paid	(436)	(279)	(406)	(609)	(796)
Finance costs, net	(111)	(140)	(106)	(114)	(113)	Others	(98)	(55)	-	-	-
JVs & associates	(2)	(17)	(42)	(26)	13	Net cash from financing	1,039	(380)	597	(609)	(796)
Exceptional	-	-	-	-	-						
Pre-tax profit	1,121	762	1,304	1,715	2,184	Net change in cash	(227)	513	1,083	(42)	198
						Beginning cash balance	3,196	2,970	3,472	4,555	4,514
Income tax	(390)	(257)	(417)	(532)	(655)	Exchange difference	1	(11)	-	-	_
Less: Minority interests	4	(8)	` <i>7</i>	Ì 15	20	Cash at the end of the year	2,970	3,472	4,555	4,514	4,712
Net profit	728	513	880	1,168	1,509	·	1,234	918	1,453	1,855	2,284

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	YE 31 Dec	FY19A	FY20A	FY21E	FY22E	FY23E
Non-current assets	3,057	3,544	3,322	3,141	3,024	Sales mix (%)					
Fixed asset	662	796	857	944	1,056	Footwear	56.9	61.8	63.0	64.3	64.7
Intangible assets & goodwill	1,738	1,528	1,287	1,045	803	Apparel	40.9	36.3	35.3	34.3	34.0
Prepaid lease payments	104	573	573	573	573	Accessories	2.3	2.0	1.7	1.4	1.3
Interest in joint ventures	197	218	176	150	163		-	-	-	-	-
Other non-current assets	356	429	429	429	429	Total	100.0	100.0	100.0	100.0	100.0
Current assets	9,266	9,027	11,252	12,742	14,163	P&L ratios (%)					
Cash and cash equivalents	2,970	3,472	4,555	4,514	4,712	Gross margin	43.4	39.1	41.5	42.0	42.7
Inventories	1,046	975	1,155	1,429	1,635	Operating margin	15.1	11.2	14.4	14.8	15.7
Trade and other receivables	2,910	3,236	3,988	4,973	5,768	Pre-tax margin	13.7	9.3	13.0	13.7	15.0
Prepayments	818	899	1,108	1,381	1,602	Net margin	8.9	6.3	8.7	9.3	10.4
Other current assets	1,522	446	446	446	446	Effective tax rate	34.7	33.0	31.0	30.5	30.2
Current liabilities	3,671	3,334	3,853	4,588	5,159	Balance sheet ratios					
Bank loans	1,086	642	642	642	642	Current ratio (x)	2.5	2.7	2.9	2.8	2.7
Trade payables	1,420	1,479	1,753	2,168	2,480	Quick ratio (x)	2.2	2.4	2.6	2.5	2.4
Accruals & other payables	981	1,052	1,296	1,617	1,875	Cash ratio (x)	0.8	1.0	1.2	1.0	0.9
Tax payables	115	86	86	86	86	Inventory turnover days	82	72	72	72	72
Others	69	75	75	75	75	Trade receivables days	130	145	145	145	145
						Trade payables days	112	109	109	109	109
Non-current liabilities	1,691	1,939	2,942	2,942	2,942	Total debt / total equity ratio (%)	34	30	41	38	35
Bank loans	1,269	1,516	1,516	1,516	1,516	Net debt / equity ratio (%)	Net cash				
CB or Preferred shares	-	-	1,003	1,003	1,003	Returns (%)					
Deferred tax	280	237	237	237	237	ROE	10.5	7.0	11.3	14.0	16.7
Others	142	186	186	186	186	ROA	5.9	4.1	6.0	7.4	8.8
						Per share					
Minority Interest	-	-	7	22	42	EPS (RMB)	0.30	0.21	0.35	0.46	0.59
Total net assets	6,960	7,299	7,773	8,332	9,044	DPS (RMB)	0.18	0.12	0.21	0.28	0.36
Shareholders' equity	6,960	7,299	7,773	8,332	9,044	BVPS (RMB)	2.79	2.87	3.05	3.27	3.55



# **Disclosures & Disclaimers**

# **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

#### **CMBIS** Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

#### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

#### For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

#### For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

#### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.